Tarsus Pharmaceuticals, Inc. (TARS) Guidance & Earnings Results
On 2026-08-06 Tarsus Pharmaceuticals, Inc. raised guidance: "FY2026 XDEMVY net product sales raised to $685-705M from prior range (not…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TARSTarsus Pharmaceuticals, Inc.Follow TARS — free
—
Price chart with a free account
- Market cap
- 3.0B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 6 Aug 26 | Raised | FY2026 XDEMVY net product sales raised to $685-705M from prior range (not stated) · full year |
| 6 May 26 | Reaffirmed | Full-year 2026 guidance of $670-700 million of XDEMVY net product sales; peak sales potential exceeding $2 billion. · full year |
| 23 Feb 26 | Raised | peak sales >$2B |
Tarsus Pharmaceuticals, Inc. — questions
- What guidance did Tarsus Pharmaceuticals, Inc. give?
- On 2026-08-06: "FY2026 XDEMVY net product sales raised to $685-705M from prior range (not stated)"
- When does Tarsus Pharmaceuticals, Inc. report earnings?
- Tarsus Pharmaceuticals, Inc.'s next earnings report is expected on 2026-11-10.
Every figure on this page comes from Tarsus Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.